Drug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza.
"Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6 mg/ml...", Zydus Cadila said in a statement.
The product is used in the treatment and prevention of influenza, it added.
The drug will be produced at Nesher Pharmaceuticals' manufacturing facility located at St Louis, US, Zydus Cadila said.
The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company's filing process.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
EXPLAINED! Anil Singhvi on his campaign to protect investors and save their hard-earned money; reveals market strategy going forward
Good news amid coronavirus! India to emerge as fastest growing G20 economy - Here is how
Cost of coronavirus lockdown: Covid 19 fight will come at high economic cost, beat 2008 crisis, say analysts